ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced results from a subgroup analysis of the phase 3 CABINET pivotal study of patients with extra-pancreatic neuroendocrine ...
Add Yahoo as a preferred source to see more of our stories on Google. In NCFB On 30 September 2025, at the European Respiratory Society (ERS) Conference, held in Amsterdam, the Netherlands, Insmed ...
SENIOR-RITA subgroup data showed primary composite events in 37.7% with invasive therapy versus 29.4% with conservative care ...
ALAMEDA, Calif.--(BUSINESS WIRE)-- Exelixis, Inc. (EXEL) (Nasdaq: EXEL) today announced results from a subgroup analysis of the CABINET phase 3 pivotal trial evaluating CABOMETYX ® (cabozantinib) ...
Lupus nephritis (LN) is one of the most serious complications of SLE, manifesting as haematuria and/or proteinuria, ...
Meaningful efficacy observed in slow-progressor subgroup; NfL biomarker improvements support potential for accelerated regulatory pathway SEOUL, South Korea, May 29, 2025 /PRNewswire/ -- Neuronata-R®, ...
MONTPELLIER, France--(BUSINESS WIRE)--Analysis of a major subgroup of patients undergoing a first Total Knee Replacement (TKR), representing over 70% of the trial population (108 out of 151), revealed ...
Please provide your email address to receive an email when new articles are posted on . Patients in this subgroup participated in the phase 3 ASPEN trial. Brensocatib given as 10 mg or 25 mg performed ...
We review Bayesian and Bayesian decision theoretic approaches to subgroup analysis and applications to subgroup-based adaptive clinical trial designs. Subgroup analysis refers to inference about ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results